look news india
Lincoln Pharmaceuticals Limited: Lincoln Pharmaceuticals, one of India's leading healthcare companies, today announced excellent operational and financial results for the first quarter of the financial year 2024-25 ending June 30, 2024. For the first quarter of the financial year 2024-25, the Company reported a standalone net profit of Rs. 23.67 crores as against a standalone net profit of Rs. 19.01 crores, showing a growth of 24.51 per cent year-on-year.
Total revenue for the quarter ended June 2024 was Rs. 157.69 crore as against Rs. 143.31 crore for the first quarter of FY2024, up 10.03 percent YoY over total revenue. EBITDA for the first quarter of FY2025 was Rs. 33.14 crore as against Rs. 28.41 crore for the first quarter of FY2024, up 16.65 percent YoY. EPS per share for the first quarter of FY2025 was Rs. 11.37.
Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Ltd, said, the company has shown exceptional operational and financial results in the first quarter of FY 2025. Both domestic and export operations have witnessed strong growth. We are confident that maintaining a strong growth path will lead to improved profitability and margins going forward. With strategic expansion in new territories as well as a pipeline of new product launches for domestic and international markets, the company aims to strengthen its market position and achieve a revenue target of Rs. 750 crore by the end of FY 2026.
During FY24, the company's net profit grew 28.6 percent year-on-year to Rs. 93.37 crore, EBITDA grew 20.3 percent to Rs. 134.33 crore and total income grew 15.43 percent to Rs. 614.97 crore. For FY24, the company posted its highest and best ever financial year results with the highest ever revenue, EBITDA and net profit.
With specific growth strategies and business expansion plans for value-added products and expansion into new markets, the company expects to reach Rs. 750 crore revenue target. Foreign institutional investors (FIIs) increased their stake in the company from 1.74 per cent in June 2023 to 3.95 per cent by June 2024.
